GlassScriptPhysician profile
Jackson T Brown
NPI 1972181469
$863.26
in general payments reported to CMS, 2019-2025
18 companies · $476 in 2025
The $476 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $387 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $863.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $167.79 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $131.80 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $81.61 | 2024-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $68.42 | 2024-2025 | Cologuard Collection Kit |
| Abbvie INC. | $61.64 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $56.75 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $45.62 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Antares Pharma, INC. | $44.46 | 2025 | Xyosted |
| Amgen INC. | $33.23 | 2024-2025 | Evenity, Prolia, Repatha |
| Phathom Pharmaceuticals, INC. | $23.50 | 2025 | Voquezna |
| Vivus LLC | $22.89 | 2025 | Pancreaze |
| Sanofi-Aventis U.S. LLC | $21.42 | 2025 | |
| Mylan Specialty L.P. | $20.86 | 2024 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.51 | 2025 | Xifaxan |
| Pfizer INC. | $17.15 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $16.40 | 2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.12 | 2025 | Jardiance |
| Dynavax Technologies Corporation | $14.09 | 2024 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jackson Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.